Intuitive Surgical's stock has fallen about 38% due to concerns over valuation and slowing U.S. procedure growth, despite strong Q2 2026 earnings and raised guidance. The decline is linked to expiring ACA subsidies affecting elective surgeries and reduced demand for bariatric procedures due to weight loss drugs. The stock's current valuation appears to overstate these challenges, presenting a potential buying opportunity for investors. Market reaction highlights the tension between short-term headwinds and the company's underlying financial strength.
Intuitive Surgical's stock has fallen nearly 30%, but the company remains a buy due to resilient adoption metrics and strong growth in system placements and installed base. Despite softer U.S. procedure growth, profitability improved with Q2 non-GAAP...
Several key stocks fell significantly due to company-specific issues. Intuitive Surgical's shares dropped 14.15% despite strong earnings because of slower growth in surgical procedures, impacting related leveraged ETFs. REGENXBIO's stock fell 11.7% a...
Intuitive Surgical reported solid Q2 results, beating revenue and earnings estimates with a 20% increase in da Vinci procedures and a gross margin of 70%. Despite recent market challenges, the company's valuation is near a 5-year low at about 35 time...
Intuitive Surgical reported strong Q2 earnings with adjusted EPS of $2.80, surpassing analyst expectations due to high demand for its da Vinci robotic surgical systems. Despite the positive results, the stock dropped 12% in premarket trading after th...
Intuitive Surgical reported Q2 revenue of $2.89 billion and adjusted earnings of $2.80 per share, beating analyst estimates. However, shares fell 11% as US procedure growth slowed to 12% from 14% in Q1, attributed to deferred treatments and changes i...
